Stock IGX INTELGENX TECHNOLOGIES CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights IntelGenx Technologies Corp. OTC Bulletin Board

Equities

IGX

US45822R1014

End-of-day quote OTC Bulletin Board
Other stock markets
- CAD - Intraday chart for IntelGenx Technologies Corp.
06-11 IntelGenx Reports Launch of Sale and Investment Solicitation Process MT
05-28 IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
IntelGenx Reports Launch of Sale and Investment Solicitation Process
MT
IntelGenx Brief: Says Obtained Court-Approval of a Sale and Investment Solicitation Process; Had Recently Initiated Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
MT
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp..
CI
IntelGenx Begins Restructuring Proceedings Under CCAA to Implement Review of Strategic Alternatives
MT
IntelGenx Brief: Initiating Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
MT
IntelGenx Technologies Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial
CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA
CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises
MT
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million
MT
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats
CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm
MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm
CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm
MT
IntelGenx Announcing Shareholder Approval of Financing Transactions
MT
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease
MT
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease
CI
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGXT Stock
  4. IGX Stock
  5. News IntelGenx Technologies Corp.
  6. Highlights